Beyond the indulgences of tech billionaires including Bryan Johnson – who has spent millions on longevity interventions (including plasma infusions from a teenage son) – can the rest of us expect to live into our hundreds?

Amol Sarva, founder of a venture fund investing in longevity research, and Joel Jackson, co-founder and president of a healthtech company trying to extend lifespans, discuss how tech advances including AI and personalised medicine could help extend life spans to 150 years or more.

Amol and Joel explore recent progress in targeting diseases of ageing, as well as fundamental biological ageing. While human immortality in 20 years seems unlikely, breakthroughs that slow the ageing process are possible. But ethical questions remain around fair access.

Amol Sarva, managing partner at Life Extension Ventures, and Joel Jackson, co-founder and president of Lifeforce, were in conversation with Yuliya Sotska, chief brand and communications officer for Viseven, on HealthConf at Collision 2023.